Fig. 4From: Nonselective beta-adrenoceptor blocker use and risk of Parkinson’s disease: from multiple real-world evidenceMR association between ADRB1 or ADRB2 and PD risk. ADRB1, β1 adrenergic receptor; ADRB2, β2 adrenergic receptor; CI, confidence interval; MR, Mendelian randomization; OR, odds ratio; PD, Parkinson’s diseaseBack to article page